LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.71.
Several analysts have recently commented on the stock. BTIG Research dropped their price objective on shares of LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Zacks Research raised shares of LifeMD from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Lake Street Capital decreased their target price on shares of LifeMD from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, November 13th. Mizuho decreased their target price on shares of LifeMD from $7.00 to $6.00 and set an "outperform" rating for the company in a research report on Friday, November 13th. Finally, B. Riley Financial assumed coverage on shares of LifeMD in a report on Friday, September 11th. They issued a "buy" rating and a $8.00 price target on the stock.
View Our Latest Research Report on LifeMD
LifeMD Stock Performance
Shares of LFMD stock opened at $1.45 on Friday. The stock's 50-day simple moving average is $2.47 and its 200-day simple moving average is $3.53. The firm has a market capitalization of $69.84 million, a PE ratio of -24.08 and a beta of 2.19. LifeMD has a fifty-two week low of $1.38 and a fifty-two week high of $5.38.
LifeMD (NASDAQ:LFMD - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $44.63 million during the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a negative return on equity of 188.63% and a negative net margin of 0.25%. Sell-side analysts forecast that LifeMD will post -0.48 earnings per share for the current year.
Hedge Funds Weigh In On LifeMD
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in LifeMD by 8.0% during the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company's stock worth $12,533,000 after acquiring an additional 225,510 shares during the period. State Street Corp lifted its holdings in LifeMD by 22.6% in the second quarter. State Street Corp now owns 1,318,784 shares of the company's stock valued at $5,447,000 after acquiring an additional 243,376 shares during the period. Marshall Wace LLP lifted its holdings in LifeMD by 45.1% in the third quarter. Marshall Wace LLP now owns 809,138 shares of the company's stock valued at $2,347,000 after acquiring an additional 251,664 shares during the period. Walleye Capital LLC purchased a new stake in LifeMD in the 2nd quarter worth approximately $1,338,000. Finally, Russell Investments Group Ltd. boosted its position in LifeMD by 5,801.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company's stock worth $1,300,000 after purchasing an additional 309,436 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.
About LifeMD
(
Get Free Report)
LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men's health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.
While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.